Effect of enzyme therapy in juvenile patients with Pompe disease: A three-year open-label study-Reference-Cited by-同舟云学术

Effect of enzyme therapy in juvenile patients with Pompe disease: A three-year open-label study

Published:2010-12 Issue:12 Volume:20 Page:775-782
ISSN:0960-8966
Container-title:Neuromuscular Disorders
language:en
Short-container-title:Neuromuscular Disorders

Author:

van Capelle C.I.,van der Beek N.A.M.E.,Hagemans M.L.C.,Arts W.F.M.,Hop W.C.J.,Lee P.,Jaeken J.,Frohn-Mulder I.M.E.,Merkus P.J.F.M.,Corzo D.,Puga A.C.,Reuser A.J.,van der Ploeg A.T.

Funder

European Union

ZonMw –Dutch organization for healthcare research and innovation of care

The Prinses Beatrix Fund

Publisher

Elsevier BV

Subject

Genetics (clinical),Neurology (clinical),Neurology,Pediatrics, Perinatology and Child Health

Reference45 articles.

1. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency;Hirschhorn,2001

2. Acid maltase deficiency;Engel,1994

3. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease;Thurberg;Lab Invest,2006

4. Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease;Fukuda;Ann Neurol,2006

5. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients;Hagemans;Brain,2005

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement;International Journal of Molecular Sciences;2023-08-26

2. Lentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease;Molecular Therapy - Methods & Clinical Development;2022-06

3. What’s new and what’s next for gene therapy in Pompe disease?;Expert Opinion on Biological Therapy;2022-04-27

4. Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease;Orphanet Journal of Rare Diseases;2022-02-02

5. Six-Minute Walk Distance Is a Useful Outcome Measure to Detect Motor Decline in Treated Late-Onset Pompe Disease Patients;Cells;2022-01-20